Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill.
Cyberattacks Intensify Pressure on Latin American Governments
Cyber threats across Latin America are increasingly targeting government systems, from disruptive attacks in Puerto Rico to a surge of probes against Colombia’s health sector.
Novo cuts 400 jobs in Indiana as Scholar Rock refiles drug linked to the factory
Novo Nordisk is laying off roughly 400 staffers at the Bloomington, IN, factory it recently acquired, after manufacturing issues led the FDA to reject drugs from three separate companies that had contracted with the facility. …
Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Now Eli Lilly has an obesity pill, too. On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to …
Channel Allocation and Equity in Preventive Campaigns for Older Adults: Agent-Based Modeling Study
Background: Preventive campaigns for older adults must decide how to allocate limited resources across media channels. However, these channel allocation and budget decisions rarely use explicit criteria for distributional equity or structured strategic planning tools. Consequently, health systems may optimize average uptake while leaving large gaps across socioeconomic groups and media use profiles. Objective: This […]
Digital Primary Health in Rwanda: Qualitative Study of User Experiences and Implementation Lessons From Babyl’s Telemedicine Platform
Background: Digital health innovations address health care accessibility challenges in low- and middle-income countries. Babyl, Rwanda’s largest telemedicine platform, reached 450 of 510 health facilities and enrolled 2 million patients before halting in September 2023 for system redesign. Limited research has explored implementation experiences and user perspectives that influenced its sustainability. Objective: This study aims […]
Amgen, Zai Lab team up on DLL3; Janux gets $35M milestone payment
Double the DLL3: Amgen and Zai Lab are collaborating on a Phase 1b study that combines the former’s T cell engager Imdelltra and the latter’s experimental antibody-drug conjugate, known as zocilurtatug pelitecan, in an aggressive …
DNA testing can help right racial imbalance in breast cancer
Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Paragon offshoot Korsana to go public in reverse merger for Alzheimer’s work
Jonathan Violin loves a reverse merger, and so does Paragon Therapeutics. Violin is taking Korsana Biosciences’ fight against Alzheimer’s public. Korsana will gain access to more capital as it rides the tailwinds of Roche’s similar …
How a 20-year old asthma drug is boosting food allergy research
Peanut bans at schools. EpiPen training at summer camps. Parents struggling to find an alternative to PB&J. The massive rise in food allergies transformed how many American children grow up. But a combination of better …
IO Biotech will file for bankruptcy after failure of cancer vaccine in key trial
The Danish cancer vaccine developer IO Biotech will shut down, according to a Tuesday SEC filing announcing its intent to seek bankruptcy protection. Last August, IO Biotech’s cancer vaccine narrowly failed …
Venom Stealer MaaS Platform Commoditizes ClickFix Attacks
A new service on the cybercrime market provides automated capabilities to create persistent information-stealing social engineering attacks.